Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.

You may also be interested in...



Heptares And Complix Raise Series B Funds To Advance Preclinical Compounds

GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.

Cubist Is Latest Heptares Collaborator On GPCR-Targeted Drugs

U.S. acute hospital care specialist Cubist has become the sixth major pharma company to collaborate with U.K.-based Heptares on finding novel therapeutics that interact with G-protein coupled receptors.

Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University

This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073904

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel